Today, April 20, 2022, Nasdaq is trading at $13.522 and the S&P500 at $4,468. The Dow Jones today trades at $35,157.

We have listed below the best stocks to buy now today

1.Viatris (NASDAQ:VTRS)

What You Need To Know About Viatris (NASDAQ:VTRS)

There was a 1.96% increase in the price of Viatris (NASDAQ:VTRS) on the last trading day. This rise overtook the S&P 500’s 1.61% daily rise. The Nasdaq’s high-tech index rose 0.05 percent, while the Dow gained 1.45 percent.

As of today’s close, generic drug stocks were down 0.56 percent from a month earlier, outpacing the medical sector’s 0.95 percent decline and the S&P 500’s 1.42 percent decline.

Wall Street will keep an eye on Viatris as the next earnings report date approaches. May 9, 2022, is likely to be the date. Analysts estimate that Viatris will earn $0.84 per share in this report. That is an 8.7 percent decrease from the previous year’s figures. In addition, according to the most current analyst consensus estimate, they are expected to have quarterly sales of $4.28 billion, down 3.37% from a year ago.

Experts forecast $3.46 a share in earnings and $17.36 billion in sales for the year. These numbers represent decreases of -6.49 percent and decreases of -2.92 percent from the previous year.

Analysts’ forecasts for Viatris have recently undergone some revisions, which investors should watch. These latest changes reflect the changing nature of short-term business trends. As a result, the upwardly revised estimates show that analysts remain optimistic about the company’s growth and profitability prospects.

According to analyst calculations, Viatris’ forward P/E ratio is 3.09. Viatris sells at a discount to its industry, which has an average forward P/E of 24.67. Also, VTRS has a PEG ratio of 0.46 at writing. The company’s expected earnings growth rate is also considered when calculating the PEG ratio, making it comparable to the well-known P/E ratio. At yesterday’s close, the Medical Services sector had an average PEG index of 1.68.

2.Cummins(NYSE:CMI)

CMI Stock: $233 Price Target and Hold Rating by Amit Chowdhry 

Deutsche Bank has set a $233 price objective on Cummins Inc. (NYSE: CMI) shares. The specifics are here. At the time of writing, Deutsche Bank had a $233 price objective on Cummins Inc. There is also a “Hold” rating from Deutsche Bank analyst Nicole DeBlase.

Shares of Cummins Inc. CMI rose by 0.39 percent to $196.71 on Monday. That was the third straight day that the stock had gained ground. However, the supply of Cummins Inc. fell by 76.94 percent from its 52-week high ($273.65), set on May 10.

A logo for Cummins, Inc. (NYSE:CMI) On Friday morning, Zacks Investment Research released a research note that raised shares of Cummins from a sell rating to a hold recommendation. The stock has a price objective of $204.00 at Zacks Investment Research.

One of the most promising developments for Cummins in recent years has been the purchase of a 50 percent ownership in Momentum Fuel and several strategic relationships. In addition, optimistic sales predictions and solid financial results inspire confidence. 

In the first half of 2022, supply chain interruptions and rising commodity prices will pressure the firm’s profitability. Cummins expects its earnings to be slashed by the New Power segment’s ongoing losses, increasing capital expenditures, and rising operating costs. investors should wait for a better time to enter the market before making a purchase.”

3.UnitedHealth Group(NYSE:UNH)

Price Target Increased for UnitedHealth Group (NYSE:UNH) to $600.00

In a report issued on Tuesday, research analysts at BMO Capital Markets raised their price target on UnitedHealth Group (NYSE:UNH) from $510.00 to $600.00. The shares of the healthcare giant currently have a rating of “market perform” at the brokerage. BMO Capital Markets’ target price indicates a 12.34 percent upside from the previous close.

UNH has been the subject of recent commentary from several other experts. On Monday, analysts gave the stock a “buy” recommendation. In a research note on Monday, Royal Bank of Canada set a $563.00 valuation target for UnitedHealth Group and issued a “outperform” rating. 

In a research note released on Monday, Morgan Stanley upgraded UnitedHealth Group from a “neutral” rating to an “overweight” recommendation. In addition, UH, ‘s shares have risen from $512.00 to $596.00 in a Cowen report released on Monday.

On Tuesday, the stock of NYSE:UNH started at $534.08. The 52-week low for UnitedHealth Group is $383.12, and the 52-week high is $553.29. Short-term liquidity is 0.79, while the company’s debt to equity ratio is 0.54. P/E of 29.23, a price-to-earnings-grow ratio of 1.67, a beta of 0.88, and a market capitalization of $502.52 billion. The company’s 50-day and 200-day moving averages are $499.32 and $473.49.

According to the company, the most recent earnings report from UnitedHealth Group (NYSE:UNH) was released on Thursday, April 14. The healthcare company topped Thomson Reuters’ average estimate of $5.38 per share by $0.11, posting quarterly profits per share of $5.49.

In the most recent quarter, the firm made $80.15 billion in sales, more than the $78.77 billion average expectation. There was a 5.86 percent net margin and a return on equity of 24.74 percent for UnitedHealth Group in the third quarter. Revenue at UnitedHealth Group increased by 14.2 percent in the most recent quarter compared to the previous year’s same period. 

Earnings per stock during the same quarter the previous year were $5.31. Sell-side analysts expect UnitedHealth Group to generate an average EPS of 21.66 in the current fiscal year.

4.Ecolab (NYSE:ECL)

Ecolab (ECL) Is Expected to Report Earnings for the Third Quarter on Tuesday

On Tuesday, April 26, Ecolab (NYSE:ECL) is set to release its quarterly earnings data. Ecolab’s quarterly profits are expected to be $0.82 per share. 

On Tuesday morning, there was a $175.04 opening price for ECL’s shares. There are 52-week lows and 52-week highs for Ecolab’s stock. 50-day moving averages are $175.62, and 200-day moving averages are $204.79 for this stock. 

There are quick ratios of 0.90, 1.32, and 1.15, respectively, for the firm. The stock has a market value of $50.11 billion, a P/E of 44.77, a P/E growth of 2.62, and a beta of 1.09.

On Friday, April 15, the company paid out a quarterly dividend. A dividend of $0.51 per share was paid to shareholders of record on March 15. The dividend yield is 1.17 percent annually or $2.04 per shareholder. Ecolab has a dividend payout ratio (DPR) of 52.17 percent.

The stock was given a rating of “hold” by the analysts. Eleven analysts have assigned the stock a hold rating, while five have recommended that investors consider buying the stock. MarketBeat.com reports that the business has a consensus “Hold” rating and an average price target of $206.27 on its stock.

According to a press release from the firm, Director Jeffrey M. Ettinger purchased 5,000 shares of Ecolab stock on February 17. It spent an average of $179.39 per share to buy the claims totaling $896,950.00. The transaction was made public in a legal filing with the Securities and Exchange Commission (SEC). As a result, insiders now own 1.04% of the company’s stock.